In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Prolonged QTc interval in ECG predicts long-term mortality in ICU patients

Session Poster Session 3

Speaker Tuija Sabell

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Biomarkers
  • Session type : Poster Session

Authors : T Javanainen (Paris,FR), R Cinotti (Paris,FR), K Cerlinskaite (Paris,FR), S Ishihara (Paris,FR), E Akiyama (Paris,FR), N Vodovar (Paris,FR), E Gayat (Paris,FR), A Mebazaa (Paris,FR)

T Javanainen1 , R Cinotti1 , K Cerlinskaite1 , S Ishihara1 , E Akiyama1 , N Vodovar1 , E Gayat1 , A Mebazaa1 , 1Hospital Lariboisiere, Inserm UMR-S 942 and Anesthesia and Critical Care Department - Paris - France ,



Prolonged QTc interval in ECG is a common finding in Intensive Care Unit (ICU). It has been associated with higher mortality in population based studies, but there is little information about the association with long-term mortality in critically ill patients.


The aim was to investigate the association between prolonged QTc and long-term prognosis in ICU patients.


FROG-ICU (NCT 01367093) is a prospective, observational study conducted in 21 ICUs in 14 European hospitals. In this sub-study, patients with at least one ECG available during the first 3 days after ICU admission were included. QT was measured digitally on standard 12-lead ECG, and it was corrected with Bazett's formula. Prolonged QTc was defined as QTc=450ms in male and QTc=460ms in female patients. For 1-year mortality analysis, adjusted cox model was formed including Simplified Acute Physiology Score II (SAPS II), Charlson Comorbidity Index, gender, amiodarone treatment, hs-TnI at inclusion and acute cardiac arrest or cardiogenic shock as cause for ICU admission.


Of the 2087 FROG-ICU patients, 1597 (77%) were included in this study. 421 (26%) patients displayed with prolonged QTc. These patients were older (63 (±15) vs. 59 years (±17), p<0.001), more often male (312 (74%) vs. 700 (60%), p<0.001) and had more comorbidities. Amiodarone administration and acute cardiac arrest as cause for ICU admission were more common in prolonged QTc patients (Table) and hs-TnI was higher (60 ng/l (16-340) vs. 30 ng/l (7-199), p<0.001). 1-year mortality was higher in patients with prolonged QTc (182 (43%) vs. 373 (32%), p<0.001, Figure). In adjusted mortality analysis, prolonged QTc remained predictor of 1-year mortality (HR 1.29-IC95% (1.08-1.55), p=0.006).


Prolonged QTc during the first 3 days after ICU admission is a marker of long-term mortality in ICU patients.

Normal QTc (n=1176) Prolonged QTc (n=421) p-values
Age, years (SD) 59 (17) 63 (15) <0.001
Male gender, n (%) 700 (60) 312 (74) <0.001
Charlson Comorbidity index, n (%) 2.9 (2.3) 3.5 (2.4) <0.001
SAPS II, n (%) 48 (19) 52 (19) 0.003
Cardiogenic shock, n (%) 63 (5) 34 (8) 0.059
Acute cardiac arrest, n (%) 80 (7) 52 (12) 0.001
Amiodarone treatment, n (%) 196 (17) 121 (29) <0.001
Neuroleptic administration, n (%) 133 (11) 40 (10) 0.351
hs-TnI, ng/L (IQR) 30 (7-199) 60 (16-340) <0.001
Baseline characteristics.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are